|
1
|
Wang X, Zhang X, Zhang S, Zhang L, Shen J, Zhang Y, Zhang H, Zhang MR, Wang R, Hu K. Development of Cyclic Peptide-Based Radiotracers for uPAR. ChemMedChem 2025; 20:e202500061. [PMID: 40312769 DOI: 10.1002/cmdc.202500061] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [Abstract] [Key Words] [MESH Headings] [Grants] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Received: 01/22/2025] [Revised: 02/22/2025] [Indexed: 05/03/2025]
Abstract
The urokinase plasminogen activator (uPA) system has garnered attention as a promising biomarker, with the uPA receptor (uPAR) playing a central role in system regulation and demonstrating strong associations with tumorigenicity, invasion, and metastasis. Radioligands targeting uPAR have emerged as powerful tools for the early diagnosis and treatment of malignant tumors. In this study, we developed and evaluated three novel cyclic peptide-based positron emission tomography (PET) radioligands, denoted as [⁶⁴Cu]CARP-1, [⁶⁴Cu]CARP-2, and [⁶⁴Cu]CARP-3, for uPAR imaging. These radioligands differ in the chiral configuration of their disulfide bond crosslinkers, which influences their binding ability and pharmacokinetic profiles. Among the three, [⁶⁴Cu]CARP-2 demonstrated optimal tumor radioactivity accumulation, specificity, and favorable pharmacokinetics in an MC38 tumor-bearing mouse model. Compared to [⁶⁴Cu]DOTA-AE105, a well-characterized radiotracer currently under clinical investigation, [⁶⁴Cu]CARP-2 exhibited reduced non-specific uptake and rapid clearance from normal tissues. These attributes highlight its potential as a diagnostic tool with improved imaging accuracy. The promising preclinical performance of [⁶⁴Cu]CARP-2 underscores its potential for further clinical investigation as a uPAR-targeting radiotracer.
Collapse
Affiliation(s)
- Xingkai Wang
- State Key Laboratory of Bioactive Substance and Function of Natural Medicines, Institute of Materia Medica, Chinese Academy of Medical Sciences and Peking Union Medical College, No. 1 Xian Nong Tan Street, Beijing, 100050, China
| | - Xu Zhang
- State Key Laboratory of Bioactive Substance and Function of Natural Medicines, Institute of Materia Medica, Chinese Academy of Medical Sciences and Peking Union Medical College, No. 1 Xian Nong Tan Street, Beijing, 100050, China
| | - Siqi Zhang
- State Key Laboratory of Bioactive Substance and Function of Natural Medicines, Institute of Materia Medica, Chinese Academy of Medical Sciences and Peking Union Medical College, No. 1 Xian Nong Tan Street, Beijing, 100050, China
| | - Lulu Zhang
- Department of Nuclear Medicine, Nanjing First Hospital, Nanjing Medical University, Nanjing, 211166, China
| | - Jieting Shen
- State Key Laboratory of Bioactive Substance and Function of Natural Medicines, Institute of Materia Medica, Chinese Academy of Medical Sciences and Peking Union Medical College, No. 1 Xian Nong Tan Street, Beijing, 100050, China
| | - Yingzi Zhang
- Department of Orthopaedics, the Second Affiliated Hospital of Soochow University, Suzhou, 215031, China
| | - Hailong Zhang
- Key Laboratory of Preclinical Study for New Drugs of Gansu Province, School of Basic Medical Sciences & Research Unit of Peptide Science, Chinese Academy of Medical Sciences, Lanzhou University, Lanzhou, 730000, China
| | - Ming-Rong Zhang
- Department of Advanced Nuclear Medicine Sciences, Institute for Quantum Medical Science, National Institutes for Quantum Science and Technology (QST), Chiba, 263-8555, Japan
| | - Rui Wang
- State Key Laboratory of Bioactive Substance and Function of Natural Medicines, Institute of Materia Medica, Chinese Academy of Medical Sciences and Peking Union Medical College, No. 1 Xian Nong Tan Street, Beijing, 100050, China
| | - Kuan Hu
- State Key Laboratory of Bioactive Substance and Function of Natural Medicines, Institute of Materia Medica, Chinese Academy of Medical Sciences and Peking Union Medical College, No. 1 Xian Nong Tan Street, Beijing, 100050, China
| |
Collapse
|
|
2
|
Mamat C. Editorial for the special Issue "Jörg Steinbach". J Labelled Comp Radiopharm 2020; 62:350-351. [PMID: 31141614 DOI: 10.1002/jlcr.3773] [Citation(s) in RCA: 1] [Impact Index Per Article: 0.2] [Reference Citation Analysis] [Abstract] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Received: 05/20/2019] [Accepted: 05/20/2019] [Indexed: 12/14/2022]
Abstract
This special issue of Journal of Labelled Compounds and Radiopharmaceuticals is dedicated to commemorate the outstanding scientific work of Jörg Steinbach, former director of the Institute of Radiopharmaceutical Cancer Research at the Helmholtz-Zentrum Dresden-Rossendorf (HZDR) and full professor for Bioinorganic and Radiopharmaceutical Chemistry at the Technical University Dresden. Current legal regulations brought to an end the formal attachment of Professor Steinbach to the TU Dresden as well as the directorship of the institute within his 65th birthday. A festive symposium has been held at the HZDR on the occasion of his retirement on September 5th, 2018, one day after the inauguration of the new Centre for Radiopharmaceutical Tumor Research at the HZDR.
Collapse
Affiliation(s)
- Constantin Mamat
- Institut für Radiopharmazeutische Krebsforschung, Helmholtz-Zentrum Dresden-Rossendorf, Dresden, Germany
| |
Collapse
|